Nika Pharmaceuticals, Inc. (NIKA) Progress Update

Rhea-AI Summary

Nika Pharmaceuticals (OTCQB: NIKA) provided a progress update on Dec 3, 2025. CEO Dimitar Savov discussed 2026 plans on a podcast and said 2026 will be a crucial year.

Nika Europe is finalizing the technical project for a pharmaceutical factory described as a "building within a building," with construction expected to start soon and factory completion targeted by the end of Q1 2026.

The production line equipment has $387,088 paid and is in final testing before shipment. Management noted technical planning took longer than expected and disclosed major component costs: the water for injections system near $500,000 pre-tax and the advanced HVAC system over $1.1 million pre-tax.

Positive

• Factory completion targeted by end of Q1 2026
• Production equipment $387,088 already paid and in final testing
• Technical project finalized by Nika Europe enabling imminent construction

Negative

• Technical project took longer than initially expected
• Major pre-tax component costs: WFI ~$500,000 and HVAC >$1.1M

Key Figures

Equipment pre-paid: $387,088 WFI system cost: nearly $500,000 pre-tax HVAC system cost: more than $1.1 million pre-tax +5 more

8 metrics

Equipment pre-paid $387,088 Production line equipment already paid

WFI system cost nearly $500,000 pre-tax Water for injections (WFI) system for factory

HVAC system cost more than $1.1 million pre-tax Advanced HVAC system for pharmaceutical factory

Q3 2025 net loss $7,999 Quarter ended September 30, 2025

Nine‑month net loss $39,309 Nine months ended September 30, 2025

Cash balance $6,287 As of Q3 2025 report

Current liabilities $284,164 As of Q3 2025 report

Shares outstanding 1,039,836,001 shares As of November 7, 2025

Market Reality Check

Price: $0.3800 Vol: Volume 2,166 is below the...

normal vol

$0.3800 Last Close

Volume Volume 2,166 is below the 20-day average of 2,719 (relative volume 0.8). normal

Technical Shares at 0.26 are trading below the 200-day moving average of 0.9.

Peers on Argus

NIKA gained 11.96% while peers showed mixed, mostly modest moves, with several u...

NIKA gained 11.96% while peers showed mixed, mostly modest moves, with several up low single digits and one peer slightly negative, indicating a stock-specific reaction.

Market Pulse Summary

This announcement highlighted continued progress toward completing Nika’s pharmaceutical factory, in...

Analysis

This announcement highlighted continued progress toward completing Nika’s pharmaceutical factory, including prepayment of $387,088 for production equipment and planned investments in a WFI system and advanced HVAC. Cross-referencing the latest 10-Q, the company reported no revenue, cash of $6,287, current liabilities of $284,164, and a stockholders’ deficit of $260,539 with going-concern language. Investors may watch for funding developments and how factory completion translates into revenue generation.

Key Terms

gmp standards, water for injections (wfi), hvac system, going concern, +1 more

5 terms

gmp standards regulatory

"state-of-the-art pharmaceutical factory adhering to all GMP standards"

Good Manufacturing Practice (GMP) standards are regulatory rules that ensure products such as medicines, medical devices and certain foods are produced consistently, safely and with documented quality controls. For investors, GMP compliance is like a factory following strict recipes and hygiene: it lowers the risk of product recalls, regulatory fines and supply interruptions, protecting sales, reputation and long-term value.

water for injections (wfi) medical

"just the water for injections (WFI) system will cost nearly $ 500,000"

Water for injections (WFI) is ultra‑pure water processed and tested to meet strict pharmaceutical standards for making injectable medicines, vaccines and sterile medical products. Investors care because WFI is an essential raw material — contamination, supply interruptions or higher production costs can delay drug production, trigger regulatory actions or reduce revenue, much like a fuel shortage grounding vehicles in a delivery fleet.

hvac system technical

"with the advanced HVAC system costing more than $ 1.1 million"

An HVAC system is the heating, ventilation and air conditioning equipment that controls a building’s temperature, humidity and air quality—essentially the building’s climate-control system. Investors care because its efficiency, reliability and maintenance needs affect operating costs, property value and tenant satisfaction; like a car’s engine, a well-maintained HVAC saves fuel, avoids costly breakdowns and helps keep occupants productive and buildings compliant with safety and energy rules.

going concern financial

"disclosed “substantial doubt” about its ability to continue as a going concern"

A going concern is a business that is expected to continue its operations and meet its obligations for the foreseeable future, rather than shutting down or selling off assets. This assumption matters to investors because it indicates stability and ongoing profitability, making the business a more reliable investment. Think of it as believing a restaurant will stay open and serve customers, rather than closing down suddenly.

common control merger financial

"The company continued accounting for a common control merger"

A common control merger is a transaction where two or more businesses that share the same ultimate owner combine or rearrange assets while staying under that same ownership. For investors it matters because these deals can change how value is reported, who benefits from the move, and the cash or share math for outside holders—think of it like a family reshuffling rooms in a house: the layout changes and different residents may gain or lose space, so outsiders need to check whether the deal is fair and how it affects future returns.

AI-generated analysis. Not financial advice.

HENDERSON, Nev., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA) appeared on The Street Reports podcast where CEO Dimitar Savov shared the progress the company has made thus far and outlined what is expected for 2026, which will be a crucial year for the company. You may listen to the podcast episode here.

Additionally, NIKA’s partner, Nika Europe, is finalizing the technical project for the pharmaceutical factory and expects to begin construction soon. Given that the factory is a “building within a building”, the build up time will be short and the factory is expected to be completed by the end of Q1, 2026. The production line equipment, for which $387,088 has already been paid, is in the final testing stages before it can be shipped for installation in the factory.

“Although the technical project has taken a bit longer to complete than initially expected, that is normal due to the myriads of technical details required to build a state-of-the-art pharmaceutical factory adhering to all GMP standards” explained Savov. “To explain the complexity in simple numerical terms, just the water for injections (WFI) system will cost nearly $ 500,000 pre-tax with the advanced HVAC system costing more than $ 1.1 million pre-tax,” continued Savov. “With the launch of the factory, NIKA will develop into a strong pharmaceutical project, bringing significant value to its shareholders,” concluded Savov.

About Nika Pharmaceuticals, Inc.

Nika Pharmaceuticals, Inc. (NIKA) is a pharmaceutical company, specializing in the treatment of HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, Diabetes, and all diseases, for which strengthened cell immunity is of vital importance. NIKA's intellectual property includes six drugs in injection form – two of which have successfully undergone clinical trials with good treatment results – four drugs in tablet form, and eleven dietary supplements. NIKA’s goal is to not only achieve corporate profits, but to provide better and easier access to life-saving medicinal drugs and useful dietary supplements. Find more on www.nikapharmaceuticals.com.

Forward-looking Statement:

This press release contains forward-looking statements. Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements.” These forward-looking statements generally are identified by the words “believes,” “estimates,” “projects,” “intends,” “plan,” “can,” “will,” “would,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain.

CONTACT Clifford Redekop, Secretary
COMPANY Nika Pharmaceuticals, Inc.
PHONE (702)-326-3615
EMAIL info@nikapharmaceuticals.com
WEB www.nikapharmaceuticals.com

FAQ

When does Nika Pharmaceuticals (NIKA) expect the new factory to be completed?

Management expects the factory to be completed by the end of Q1 2026.

How much has Nika paid toward production line equipment for the NIKA factory?

The company has paid $387,088 for production line equipment, which is in final testing.

What are the major equipment costs disclosed by Nika for the factory?

Company disclosed the WFI system will cost nearly $500,000 pre-tax and the HVAC more than $1.1 million pre-tax.

Did Nika management report any delays to the factory project timeline?

Management said the technical project took a bit longer than expected but described this as normal for complex GMP facility planning.

Where did CEO Dimitar Savov outline NIKA's 2026 expectations?

CEO Dimitar Savov discussed company progress and 2026 expectations on The Street Reports podcast on Dec 3, 2025.